Odyssey Health sells neurological drug pipeline to Oragenics for $1M and 8M preferred shares

Odyssey Health, Inc.

Oragenics to acquire Odyssey's assets including concussion drug ONP-002 and NPC candidate; cash payment of $1M and 8M Series F Preferred Shares.
Transaction expected to close Q4 2023, subject to shareholder approvals and other conditions, including Oragenics having ≥$5M cash at close.
ONP-002 completed Phase 1 trial; Phase 2 preparation underway; animal studies show reduced swelling, inflammation, oxidative stress.
Odyssey management members intend to join Oragenics post-close to continue development.
Odyssey retains other assets and operations; Oragenics expands into neurological therapeutics via intranasal delivery.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Odyssey Health, Inc. entered into Asset Purchase Agreement with Oragenics, Inc. valued at $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (effective 2023-10-04).

Action: entry
Agreement: asset purchase
Counterparty: Oragenics, Inc.
Value: $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock
Effective: 2023-10-04

Exact text from the filing

On October 4, 2023, Odyssey Health, Inc. (f/k/a Odyssey Group International, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Oragenics, Inc. (“ Oragenics ” the “ Purchaser ”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Odyssey Health, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-006962

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.